95 related articles for article (PubMed ID: 15217149)
1. [New therapeutic targets in testicular cancer: contribution of molecular biology].
Paule B
Prog Urol; 2004 Apr; 14(2):243-5. PubMed ID: 15217149
[TBL] [Abstract][Full Text] [Related]
2. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success.
Jones RH; Vasey PA
Eur J Cancer; 2003 Jan; 39(2):147-56. PubMed ID: 12509945
[TBL] [Abstract][Full Text] [Related]
3. [KIT receptor in testicular seminoma].
Paule B
Prog Urol; 2005 Feb; 15(1):96-9; discussion 99. PubMed ID: 15822404
[TBL] [Abstract][Full Text] [Related]
4. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
5. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
6. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.
Kollmannsberger C; Mayer F; Pressler H; Koch S; Kanz L; Oosterhuis JW; Looijenga LH; Bokemeyer C
Cancer; 2002 Jul; 95(2):301-8. PubMed ID: 12124830
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
8. [The salvage chemotherapy for refractory testicular cancer with novel anticancer agents].
Miki T; Nomoto T; Nakagawa S; Nakao M; Nonomura N; Takada T; Saiki S; Kotake T
Hinyokika Kiyo; 1999 Nov; 45(11):811-4. PubMed ID: 10637749
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
Einhorn LH; Brames MJ; Heinrich MC; Corless CL; Madani A
Am J Clin Oncol; 2006 Feb; 29(1):12-3. PubMed ID: 16462496
[TBL] [Abstract][Full Text] [Related]
10. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue.
Strohmeyer T; Reese D; Press M; Ackermann R; Hartmann M; Slamon D
J Urol; 1995 Feb; 153(2):511-5. PubMed ID: 7529338
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
13. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.
Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O
Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490
[TBL] [Abstract][Full Text] [Related]
14. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
[TBL] [Abstract][Full Text] [Related]
15. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT.
Pedersini R; Vattemi E; Mazzoleni G; Graiff C
Lancet Oncol; 2007 Nov; 8(11):1039-40. PubMed ID: 17976614
[No Abstract] [Full Text] [Related]
16. [Molecular therapy of breast carcinoma in the advanced phase].
Foggi P; Amodio A
Tumori; 2003; 89(4 Suppl):189-91. PubMed ID: 12903589
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
[TBL] [Abstract][Full Text] [Related]
18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
19. [Salvage chemotherapy in refractory testicular cancer].
Nakao M; Nomoto T; Mizutani Y; Miki T
Gan To Kagaku Ryoho; 2000 Apr; 27(4):542-7. PubMed ID: 10790996
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
Nurmio M; Toppari J; Zaman F; Andersson AM; Paranko J; Söder O; Jahnukainen K
Int J Androl; 2007 Aug; 30(4):366-76; discussion 376. PubMed ID: 17705809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
